Goldman Sachs Raises Price Targets On Specialty Pharmaceutical Stocks On Possible M&A (AGN, MRX, KG)

September 30, 2009 12:16 PM EDT

Goldman Sachs lifted their price targets on a number of Specialty Pharmaceutical stocks today to incorporate possible future M&A in the sector. The firm sees strategic rationale as most important driver for deals. They said cash flow will be important, but buyout targets are unlikely to command significant premiums.

• Allergan (NYSE: AGN) raises price target from $60 to $62 (20% M&A weighting)
  
• Cephalon (Nasdaq: CEPH) lowers price target from $70 to $67 (15% M&A weighting)
  
• Endo (Nasdaq: ENDP) raises price target from $22 to $24 (15% M&A weighting)
  
• Forest (NYSE: FRX) raises price target from $29 to $30 (5% M&A weighting)
  
• King (NYSE: KG) raises price target from $11 to $12 (20% M&A weighting)
  
• Medicis (NYSE: MRX) raises price target from $25 to $26 (20% M&A weighting)
  
• Sepracor (Nasdaq: SEPR) raises price target from $21.60 to $22 ($23 takeover form Japan's Dainippon)

Related Categories

Analyst Comments
Rumors

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?